Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the company has agreed to acquire Verve Therapeutics. Eli Lilly and Company ...

Eli Lilly & Co. closed 20.16% below its 52-week high of $972.53, which the company achieved on August 22nd.

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

US stocks put in solid gains on Thursday, with the S&P 500 and Nasdaq both settling at new record highs, following a raft of ...

Pharmaceutical giants introduce an insurance-free pathway for top anticoagulant Eliquis, following similar direct-to-patient ...

U.S. President Donald Trump said Tuesday he is likely to impose tariffs on pharmaceuticals as soon as the end of the month, with levies on semiconductors potentially following a similar timeline.

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Key Points Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is ...

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Long Term Growth Stocks to Invest in Right Now.